title: Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy.
abstract: A 66-year-old man with castration-resistant prostate carcinoma and multiple symptomatic bone mestastases was considered for Ra-dichloride (Xofigo) therapy. Staging with Ga-PSMA-PET/CT revealed additional extensive tumor involvement of the spine without relevant uptake in bone scintigraphy. Based on this imaging result, the patient was rescheduled for a PSMA-targeted therapy. Additional Ga-PSMA-PET/CT may have a considerable benefit for patients considered for Xofigo.
authors.affiliation: From the Departments of *Nuclear Medicine and †Urology, University Hospital Münster, Münster, Germany.
authors.forename: Axel
authors.initials: A
authors.lastname: Bode
authors.forename: Kambiz
authors.initials: K
authors.lastname: Rahbar
authors.forename: Julia
authors.initials: J
authors.lastname: Konnert
authors.forename: Martin
authors.initials: M
authors.lastname: Bögemann
authors.forename: Lars
authors.initials: L
authors.lastname: Stegger
mesh_terms: D000368:Aged; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D004492:Edetic Acid / Q000031:analogs & derivatives; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006801:Humans; D008297:Male; D009842:Oligopeptides; D009942:Organometallic Compounds; D000072078:Positron Emission Tomography Computed Tomography; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use
chemical_list: D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D009842:Oligopeptides; D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C000718244:gallium 68 PSMA-11; D004492:Edetic Acid; C581106:radium Ra 223 dichloride; D011883:Radium